Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update

TORRANCE, Calif., May 13, 2022 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31, 2022 and provided a business update.

Recent Highlights

April 2022: Announced the launch of an innovative, full-service telehealth solution (https://www.endarirx.com/ask-physician) with…

Source link

Tags: Emmaus Life Sciences Inc.

Insights on the Aseptic Pharma Processing Global Market to

Letterkenny to celebrate Africa Day

RelatedPosts

FTSE 100 Live 30 January: Unilever appoints new CEO, Legal & General boss Sir Nigel Wilson to step down

Ikonisys and Integrated Gulf Biosystems Group enter into Distribution Collaboration for Distribution of the Ikoniscope20 System in the Middle East Market

Middle-East and Africa Business Jet Market

KBRA Releases Carbon Series: Cap-and-Trade Primer (North America and Europe)

Latest Post

Farm Foundation announces 2023 agricultural scholars

First-Ever Africa Vegan Restaurant Week Held on the Continent

Europe Military Helicopters Market – SIZE, SHARE, COVID-19 IMPACT & FORECASTS UP TO 2028

FTSE 100 Live 30 January: Unilever appoints new CEO, Legal & General boss Sir Nigel Wilson to step down

Ikonisys and Integrated Gulf Biosystems Group enter into Distribution Collaboration for Distribution of the Ikoniscope20 System in the Middle East Market

Subscribe to Our Newsletter

Browse by Category-

Share us